Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals financial challenges, including a shrinking cash balance and increased cash used in operations, raising liquidity concerns. Despite some positive indicators like reduced net loss and promising initial data for NDV-01, the lack of clear guidance and potential regulatory and operational risks overshadow the positives. The management's vague responses in the Q&A add to the uncertainty. Given these factors, a negative sentiment is warranted, suggesting a potential stock price decline of 2% to 8% over the next two weeks.
Cash Balance $27.1 million, down from $44.9 million as of December 31, 2024, a decrease of $17.8 million due to cash used in operations.
Cash Used in Operations $18.1 million, compared to $13 million for the same period in 2024, an increase of $5.1 million due to ongoing development efforts.
Research and Development Expense $12 million, down from $13.3 million for the first quarter of 2024, a decrease of $1.3 million primarily driven by lower study costs from completed clinical trials for REL-1017, offset by payments for sepranolone acquisition and NDV-01 in-licensing.
General and Administrative Expense $6.3 million, down from $9.7 million for the first quarter of 2024, a decrease of approximately $3.4 million primarily driven by a decrease in stock-based compensation expense.
Net Loss $17.6 million, or $0.58 per share, compared with a net loss of $21.8 million, or $0.72 per share for the first quarter of 2024, a decrease of $4.2 million due to reduced expenses.
New Product Candidates: Relmada added two unique product candidates: NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both showing promising Phase 2 data.
NDV-01 Phase 2 Data: Positive top line proof-of-concept data for NDV-01 presented at AUA 2025, showing an overall response rate of 85% and high-grade recurrence-free survival of 83%.
Sepranolone Acquisition: Relmada acquired sepranolone from Asarina Pharma, based on its broad safety database and promising Phase 2 results in Tourette syndrome.
Market Opportunity for NDV-01: Approximately 75,000 new bladder cancer cases diagnosed annually in the U.S., with 50% being high-grade disease.
Market Opportunity for Sepranolone: Sepranolone targets disorders marked by compulsive behavior, with Prader-Willi syndrome affecting about 350,000 people worldwide.
Cash Position: Relmada reported a cash balance of $27.1 million as of March 31, 2025.
R&D Expense: Research and development expenses decreased to $12 million in Q1 2025 from $13.3 million in Q1 2024.
G&A Expense: General and administrative expenses decreased to $6.3 million in Q1 2025 from $9.7 million in Q1 2024.
Development Focus: Relmada is focused on advancing NDV-01 and sepranolone through key development milestones, with plans for further studies and FDA interactions.
Financial Risks: Relmada reported a cash balance of $27.1 million as of March 31, 2025, down from $44.9 million at the end of 2024, indicating potential liquidity concerns. Cash used in operations increased to $18.1 million in Q1 2025 from $13 million in Q1 2024, which may impact future funding for development projects.
Regulatory Risks: The company is preparing for FDA interactions and further development of product supply for sepranolone, which may face regulatory hurdles that could delay clinical development.
Operational Risks: The ongoing Phase 2 studies for NDV-01 and sepranolone require significant resources and successful execution to meet clinical milestones, which poses operational risks.
Market Risks: The market for NDV-01 and sepranolone is competitive, and the success of these products depends on their ability to demonstrate superior efficacy and safety compared to existing treatments.
Development Risks: The company faces risks associated with the clinical development of its product candidates, including the potential for unfavorable trial results or adverse events that could hinder progress.
Product Candidates: Relmada added two unique product candidates, NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both showing promising Phase 2 data.
Market Opportunity: NDV-01 targets a market with approximately 75,000 new bladder cancer cases annually in the U.S., with a high recurrence rate.
Development Plans: Relmada is preparing to begin the next set of studies for NDV-01 and sepranolone, aiming to bring these programs to patients as soon as possible.
Cash Position: Relmada has a cash balance of $27 million, which supports its disciplined development plan.
Financial Outlook: Relmada expects to have better visibility into its requirements and runway as it finalizes its clinical and regulatory strategy for NDV-01 and sepranolone.
Research and Development Expense: R&D expenses for Q1 2025 totaled $12 million, a decrease from $13.3 million in Q1 2024.
Net Loss: The net loss for Q1 2025 was $17.6 million, or $0.58 per share, compared to a net loss of $21.8 million, or $0.72 per share in Q1 2024.
Cash Balance: $27.1 million cash balance as of March 31, 2025.
Cash Used in Operations: $18.1 million cash used in operations in Q1 2025.
Net Loss: Net loss for Q1 2025 was $17.6 million, or $0.58 per share.
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
The earnings call reveals several concerns: an EPS miss, increased cash burn, and reduced cash reserves, suggesting financial instability. Regulatory and competitive risks further exacerbate uncertainties. Despite some optimism in product development, unclear management responses in the Q&A and the lack of guidance add to the negative sentiment. The net loss improvement is overshadowed by operational challenges and financial concerns, leading to a predicted stock movement of -2% to -8%.
The earnings call reveals financial challenges, including a shrinking cash balance and increased cash used in operations, raising liquidity concerns. Despite some positive indicators like reduced net loss and promising initial data for NDV-01, the lack of clear guidance and potential regulatory and operational risks overshadow the positives. The management's vague responses in the Q&A add to the uncertainty. Given these factors, a negative sentiment is warranted, suggesting a potential stock price decline of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
